Affordability & Accessibility are at the heart of Intas’ manufacturing efforts in the company’s state-of-the-art plasma fractionation facility in Ahmedabad, India. In support of our philosophy of ‘Plasma Therapy for Life’, Intas plasma centre has consistently maintained a compound average growth rate (CAGR) of 30% per year – being one of the fastest-growing therapeutic areas for the company. We utilize a specially modified Cohn’s fractionation technology for maximum translation of plasma into medicinal products. Plasma fractionation combined with chromatographic operations yields pure, safe, and efficacious products. All our products are prepared from a pool of plasma sourced from healthy and qualified donors. The sourced plasma is transported to state-of-the-art cold rooms and screened for infectious diseases at multiple checkpoints. The plasma is then tested & certified negative for HBsAg, HIV I & II antibodies, HCV RNA, HIV RNA, HBV DNA, and antibodies against HCV before being considered for manufacturing. The manufacturing procedure incorporates validated orthogonal virus inactivation/removal steps, which inactivates potential viruses, further ensuring product safety. Our focus on quality & operational excellence enables robust safety, efficiency, and throughput.

We have been supplying vital plasma-derived products to hospitals in India since February 2015. To meet the ever-increasing patient needs in India and globally, we are undergoing an expansion, which will increase our fractionation capacity to 1 Million litres of plasma per annum. Our cGMP compliant unit has approvals from WHO GMP (India) & CDSCO (Central drugs standard control organization – India). We also enjoy the distinction of being the only ANVISA (Brazilian Health Regulatory Agency) approved plasma manufacturer in India.